Icosavax, Inc.
ICVX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $1 | $8 | $2 | $0 |
| % Growth | -92.5% | 382.8% | – | – |
| Cost of Goods Sold | $2 | $0 | $18 | $4 |
| Gross Profit | -$1 | $8 | -$16 | -$4 |
| % Margin | -216.7% | 98.9% | -993.3% | – |
| R&D Expenses | $65 | $39 | $18 | $4 |
| G&A Expenses | $30 | $35 | $3 | $1 |
| SG&A Expenses | $30 | $35 | $3 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$8 | -$2 | $0 |
| Operating Expenses | $95 | $66 | $19 | $5 |
| Operating Income | -$95 | -$66 | -$19 | -$5 |
| % Margin | -16,333% | -844.2% | -1,157.8% | – |
| Other Income/Exp. Net | $3 | -$1 | -$0 | $0 |
| Pre-Tax Income | -$92 | -$67 | -$19 | -$5 |
| Tax Expense | -$3 | $1 | $0 | -$0 |
| Net Income | -$88 | -$68 | -$19 | -$5 |
| % Margin | -15,199% | -871.6% | -1,187.2% | – |
| EPS | -2.23 | -3.78 | -6.67 | -0.51 |
| % Growth | 41% | 43.3% | -1,207.8% | – |
| EPS Diluted | -2.23 | -3.78 | -6.67 | -0.51 |
| Weighted Avg Shares Out | 40 | 18 | 3 | 10 |
| Weighted Avg Shares Out Dil | 40 | 18 | 3 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$94 | -$65 | -$19 | -$5 |
| % Margin | -16,185.2% | -831.9% | -1,146.2% | – |